NCT05329090View on ClinicalTrials.gov

Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

July 16, 2025

Study Completion Date

January 16, 2026

Conditions
IgA Vasculitis
Interventions
DRUG

Rituximab Injection

anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients

DRUG

placebo

placebo experimental treatment

Trial Locations (14)

13005

CHU Marseille, Marseille

13385

APHM de La Timone, Marseille

29200

Hopital La Cavale Blanche, Brest

30029

CHU Nîmes (Caremeau), Nîmes

31059

CHU Toulouse, Toulouse

37044

CHRU Bretonneau, Tours

44093

CHU Nantes, Nantes

63000

CHU Clermont Ferrand, Clermont-Ferrand

63003

CHU Clermont Ferrand, Clermont-Ferrand

67091

CHU Strasbourg, Strasbourg

69003

Hôpital Edouard Herriot, Lyon

75679

Hôpital Cochin, Paris

92150

Hôpital Foch, Suresnes

93100

Hôpital André Grégoire, Montreuil

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Hopital Foch

OTHER